Metabolic engineering of Escherichia coli for efficient production of L-alanyl-L-glutamine

doi:10.21203/rs.2.18175/v3

Download PDF

Research

Metabolic engineering of Escherichia coli for efficient production of L-alanyl-L-glutamine

https://doi.org/10.21203/rs.2.18175/v3

This work is licensed under a CC BY 4.0 License

Journal Publication

published 11 Jun, 2020

Read the published version in Microbial Cell Factories →

You are reading this latest preprint version

Background: L-alanyl-L-glutamine (AQ) is a functional dipeptide with high water solubility, good thermal stability and high bioavailability. It is widely used in clinical treatment, post-operative rehabilitation, sports health care and other fields. AQ is mainly produced via chemical synthesis which is complicated, time-consuming, labor-intensive, and have a low yield accompanied with the generation of by-products. It is therefore highly desirable to develop an efficient biotechnological process for the industrial production of AQ.

Results: A metabolically engineered E. coli strain for AQ production was developed by over-expressing L-amino acid α-ligase (BacD) from Bacillus subtilis, and inactivating the peptidases PepA, PepB, PepD, and PepN, as well as the dipeptide transport system Dpp. In order to use the more readily available substrate glutamic acid, a module for glutamine synthesis from glutamic acid was constructed by introducing glutamine synthetase (GlnA). Additionally, we knocked out glsA-glsB to block the first step in glutamine metabolism, and glnE-glnB involved in the ATP-dependent addition of AMP/UMP to a subunit of glutamine synthetase, which resulted in increased glutamine supply. Then the glutamine synthesis module was combined with the AQ synthesis module to develop the engineered strain that uses glutamic acid and alanine for AQ production. The expression of BacD and GlnA was further balanced to improve AQ production. Using the final engineered strain p15/AQ10 as a whole-cell biocatalyst, 71.7 mM AQ was produced with a productivity of 3.98 mM/h and conversion rate of 71.7 %.

Conclusion: A metabolically engineered strain for AQ production was successfully developed via inactivation of peptidases, screening of BacD, introduction of glutamine synthesis module, and balancing the glutamine and AQ synthesis modules to improve the yield of AQ. This work provides a microbial cell factory for efficient production of AQ with industrial potential.

Applied & Industrial Microbiology

Metabolic engineering

Whole-cell biocatalysis

L-amino acid α-ligase

Glutamine synthase

Glutamine (L-Gln) plays an important role in maintaining intestinal function[1-4], promoting immune function[5, 6], maintaining homeostasis of the internal environment[7] and improving the adaptability of organism to stress[8]. During disease or stress conditions, demand outpaces supply, and glutamine becomes conditionally essential[9]. The supply of exogenous L-glutamine or glutamyl dipeptide is an important nutritional solution to reduce glutamine deficiency in vivo, and can be applied in clinical treatment. However, some characteristics of glutamine such as low solubility in water, easy decomposition and poor thermal stability, as well as production of toxic pyroglutamate during heat sterilization restricted its application in medicine. Otherwise, as a result of its unstable nature, the low yield of glutamine during the purification process is a great challenge [10].

L-alanyl-L-glutamine (abbreviated as AQ) is a dipeptide of glutamine and alanine, which is more stable and water-soluble than glutamine. AQ is hydrolyzed to release glutamine and alanine in vivo. While it acts as a source of glutamine, AQ has higher bioavailability and a short half-life[11], and does not cause cumulative damage to the body, so it is used as a substitute for glutamine in clinical practice.

The commercial demand for AQ is increasing with the expansion of new applications and the development of new products based on AQ. Chemical and biotechnological methods for AQ production have been developed[12-16]. AQ can be synthesized by chemical condensation of benzyloxycarbonyl-L-alanine and methyl glutamate via activated ester[17] or triphenyl phosphine/hexachloroethane condensation, which used to require complex steps such as amino acid activation, subunit protection, and removing the protective groups. Enzymatic processes for AQ production have been developed using an α-amino acid ester acyltransferase[18, 19]. Tabata and Hashimoto engineered Escherichia coli by expressing L-amino acid α-ligase (BacD), which catalyzes the formation of AQ in an ATP-dependent manner, and produced more than 100 mM AQ in 47h of fermentation [20]. Whole-cell biocatalysis can be used to perform enzyme cascade reaction, improve catalytic efficiency, and simplify the preparation process.

A metabolically engineered E. coli strain for AQ production was developed by over-expressing L-amino acid α-ligase (BacD) from Bacillus subtilis and inactivating native peptidases. In order to use a more readily available substrate, the glutamine synthesis module based on introducing glutamine synthetase (GlnA) was constructed and optimized. Then glutamine synthesis module was combined with the AQ synthesis module to use glutamic acid and alanine for AQ production. The protein expression of BacD and GlnA was further balanced to improve the AQ production. Finally, we used the engineered strain to develop a whole-cell biocatalytic process for AQ production (Fig. 1). This work provides an environmentally friendly, highly efficient and cost-effective process for industrial biosynthesis of AQ.

Construction of the AQ Synthesis Module

The E.coli strain p01/BW25113, overexpressing BacD from Bacillus subtilis (BsBacD) which catalyzes the formation of AQ from alanine and glutamine, was constructed for the production of AQ. Extracellular AQ concentration was measured by HPLC, and 2.0 mM AQ was obtained (Fig. 2).

In E. coli, peptidases encoded by pepA, pepB, pepD and pepN, have been reported to degrade a broad spectrum of dipeptides[20, 21], and inactivating them might reduce AQ degradation. It was reported that deletion of dpp, encoding a dipeptide ABC transporter increased AQ accumulation [20, 22, 39]. By knocking out the genes pepN, pepA, pepB, pepD and dpp, the degradation of AQ was alleviated. In the starting host BW25113, 20 mM AQ was completely degraded after 3 hours, compared to only 1.3 mM in the chassis AQ09 (BW25113ΔpepN, ΔpepA, ΔpepB, ΔpepD, Δdpp) after 6 hours. A whole-cell biocatalysis system with the strain (p01/AQ09) yielded 3.3 mM AQ after 18h (Fig. 2). These results demonstrated that inactivation of peptidases and the dipeptide transporter Dpp reduced the degradation of AQ, and thus increased AQ production.

Screening of BacD homologues

BacD is the key enzyme for AQ synthesis. We examined the known sequences annotated as L-amino acid α-ligase (BacD) in the NCBI database. According to the sequences of known or predicted BacD homologs, we selected a set of related sequences from different species, and constructed a phylogenetic tree of the previously reported BacD homologs and those used in this study (Fig. S1). The genes encoding BacD homologs from different species were codon-optimized by Nanjing Generay (China) and cloned into strain AQ10 (BW25113, ∆glnEB, ∆glsAB, ∆lpxM, ∆pepABDN, ∆dpp). The performance of different BacD proteins was investigated in vivo, using the respective strains as a whole-cell biocatalysts. The result showed that the strain overexpressing BaBacD (from Bacillus altitudinis) produced higher amount of AQ (19.2 mM) than strains with other BacD homologs. By comparison, 7.9 mM AQ was obtained using the strain overexpressing BsBacD (from Bacillus subtilis) (Fig. 3). Although there was soluble expression of BvBacD (from Beta vulgaris), VcBacD (from Vibrio campbellii), and SrBacD (from Streptomyces rubrolavendulae), only 3.0, 1.8, 0.5 mM AQ was respectively obtained(Fig. 3). BsaBacD (from Bacillus safensis), BloBacD (from Bifidobacterium longum subsp. infantis), PmBacD (from Perkinsus marinus), and PfBacD (from Pseudomonas fluorescens) were expressed as inclusion bodies (Fig. S2), and only a low amount of AQ was detected.

Construction of a glutamine synthesis module

To use the more readily available substrate glutamic acid, glutamine synthetase from Corynebacterium glutamicum (CgGlnA), which convert glutamic acid to glutamine was cloned into E. coli, resulting in the strain p00/BW25113. A final glutamine titer of 22.4 mM was obtained in the whole-cell bioconversion. During growth nitrogen replete growth conditions, glutamine synthetase adenylyltransferase/deadenylase (encoded by glnE) interacts with PII-1 protein encoded by glnB, which reduces the activity of glutamine synthetase, and glnE-glnB-deficiency was reported to lead to increased glutamine accumulation [23-25]. Therefore, a glnE-glnB-deficient strain expressing GlnA (p00/AQ02) was constructed, and a glutamine titer of 27.8 mM was achieved, which was 24.1% higher than that of the strain p00/BW25113 (Fig. 4). In E. coli, glutamine was converts into glutamic acid by glutaminases GlsA (encoded by glsA) and GlsB (encoded by glsB)[26], and further into α-ketoglutarate. Consequently, the glsA and glsB genes were deleted, resulting in strain AQ04 (ΔglsAΔglsB), which was then transformed with the plasmid p00, and the resulting strain p00/AQ04 produced 33.8 mM of glutamine after 18 hours of bioconversion. Further, glnE, glnB, glsA, glsB and lpxM were sequentially knocked out and 46.5 mM glutamine was accumulated by the resulting strain p00/AQ06, with a conversion rate of 93.0 % (Fig. 4). Consequently, the strain p00/AQ06 was used for further engineering.

Combination the AQ and glutamine synthesis modules

To achieve AQ production from glutamic acid and alanine, the AQ and glutamine synthesis modules were combined. The strain AQ10 was obtained by knocking out the genes pepN, pepA, pepB, pepD, dpp, glnE, glnB, glsA, glsB and lpxM. In AQ10, the degradation of AQ was alleviated, glutamine catabolism was effectively weakened as well. After introducing BsBacD, the resulting strain p01/AQ10 produced 7.9 mM AQ, which was four times more than the production of the original strain p01/BW25113 (Fig. 2).

The engineered strains with the plasmid p11 (pYB1s-CgglnA-BsbacD), co-expressing BsBacD and CgGlnA was used as a whole-cell biocatalyst for AQ production from alanine and glutamic acid. Removal of the peptidases PepA, PepB, PepD, and PepN, together with knocking out the transporter Dpp significantly increased AQ production, and a titer of 17.9 mM was produced by the strain AQ09 harboring p11 (Fig. 5). Due to the deletion of glnE-glnB and glsAglsB, the biosynthesis of glutamine was enhanced, which resulted in increased AQ production, leading to a product titer of 29.8 mM in the strain AQ10 harboring p11 (Fig. 5). Inactivation of peptidases alleviated AQ degradation, and removing the transporter Dpp promoted the efflux of AQ. The results showed that combination of the strategies of peptidases inactivation, knocking out the transporter Dpp, and enhancing the glutamine supply by deletion of glnE-glnB and glsA-glsB greatly enhanced AQ production.

Balance of the two synthesis modules by regulating protein expression

To balance flux in the two synthesis module for the purpose of increasing AQ production, the expression of BacD and GlnA proteins was studied. To co-express BaBacD or BsBacD with CgGlnA in different order, four plasmids p11 (pYB1s-CgglnA-BsbacD), p12 (pYB1s-BsbacD-CgglnA), p13 (pYB1s-CgglnA-BabacD), and p14 (pYB1s-BabacD-CgglnA) were constructed (Fig. 6c), and used to individually transform the host AQ10. Either L-amino acid α-ligase or glutamine synthetase was poorly expressed when BaBacD was co-expressed with CgGlnA (Fig. S3), leading to decreased AQ production. However, when CgGlnA was co-expressed with BsBacD, both proteins were expressed at high levels, and contributed to an increased yield of AQ after 18h of bioconversion. The AQ titer reached 29.8 mM when CgglnA was inserted in front of BsbacD (p11/AQ10), compared to 22.3 mM when CgglnA was expressed behind BsbacD (p12/AQ10) (Fig. 6a). The concentration of the intermediate metabolite, glutamine, in p11/AQ10 (22.8 mM) was higher than in p12/AQ10 (12.0 mM) (Fig. 6a). SDS-PAGE analysis of protein expression (Fig. S3) and the concentration of glutamine suggested that higher soluble expression of CgGlnA enhanced the supply of glutamine, and increasing the expression of BsBacD might further improve the synthesis of AQ.

In order to enhance the expression of BsBacD, its native RBS was replaced to upregulate the mRNA translation initiation rate in the recombinant strain. The translation rate prediction and design of new RBS was done using RBS Calculator 2.0[27-29]. The strain p15/AQ10 expressed more BsBacD protein (Fig. S4), and its AQ production increased by 76.1 % compared to p11/AQ10 (Fig. 6b).

Optimization of the conditions for whole-cell biocatalysis

After successfully constructing an engineered E.coli strains for AQ production by metabolic engineering, we investigated its applicability as whole-cell biocatalyst for the biotechnological production of AQ. Bioconversion parameters that affect the activity of the biocatalyst, such as temperature and pH, were investigated. AQ production reached maximal values at 30 ℃ (Fig. 7a) and pH 9.0 (Fig. 7b). A decreased in pH was observed as the bioconversion proceeded, which affected the biosynthesis of AQ. It should be noted that glucose was supplemented in the reaction mixture to supply ATP for the reactions catalyzed by GlnA and BacD, it was reported that excess glucose can lead to acetate accumulation. Consequently, we measured the concentration of acetate and found that it was accumulated. To alleviate this, different glucose feeding strategies were applied to reduce acetate accumulation in the bioconversion process, including 1) 50 mM glucose at once; 2) 10 mM every 3 hours; and 3) 20 mM every 3 hours. When a low concentration of glucose (10 mM) was fed every three hours (Fig. 7c), glucose was fully utilized (Fig. S5a), and only a small amount of acetic acid accumulated (Fig. S5b ), indicating that 10mM glucose fed every three hours matched AQ productivity. The time profiles of the bioconversion indicated that alanine was exhausted first, and the ratio of glutamic acid to alanine was investigated (Fig.7d). Under feeding with 10 mM glucose every three hours at 30 ℃ and pH 9.0, the strain p15/AQ10 produced 71.7 mM AQ, from 100 mM glutamic acid and 125 mM alanine, after 18 hours of reaction, corresponding to a productivity of 3.98 mM/h. Moreover, a conversion rate of 71.7% was achieved for glutamic acid representing a 100% increase compared to the conversion rate before the optimization.

In this study, we constructed a metabolically engineered E. coli strain for AQ production by overexpressing L-amino acid α-ligase from Bacillus subtilis, knocking out peptidases PepA, PepB, PepD, and PepN, as well as the transporter Dpp, which effectively weakened AQ degradation. To use a more readily available and cheaper substrate, a module for the synthesis of glutamine from glutamic acid was constructed by overexpressing glutamine synthetase from Corynebacterium glutamicum. It was reported that the glutaminases GlsA-GlsB convert glutamine to glutamic acid, which is the main pathway of glutamine catabolism, while GlnE interacts with GlnB to induce the adenylation of glutamine synthetase under nitrogen-rich growth, leading to a reduction of the activity of glutamine synthetase. Thus, GlsA, GlsB, GlnE, and GlnB were blocked, which resulted in increased glutamine supply with a 93.0 % bioconversion of glutamic acid. Then AQ and glutamine synthesis modules were coupled, and 29.8 mM AQ production was achieved by co-expressing BsBacD and CgGlnA. To balance the flux through two modules, the expression of BacD and GlnA was fine-tuned by modifying the RBS, and AQ production was further increased by 76.1%. Finally, the reaction conditions for the whole-cell biocatalysis were optimized, and 71.7 mM AQ was obtained using strain p15/AQ10 after 18 hours of reaction, with productivity of 3.98 mM/h and a conversion rate of 71.7% from glutamic acid to AQ was achieved.

Both fermentation and enzymatic processes for AQ production were reported. We compared the AQ biosynthesis results obtained in this study with previous studies, as shown in Table. 1. Enzymatic processes were reported for AQ production from L-alanine methyl ester hydrochloride (AlaOMe) and glutamine using amino acid ester acyltransferase[18, 32, 33]. The substrates used in the process, AlaOMe and glutamine are expensive, making the process not economically feasible. Tabata and Hashimoto reported a fermentative process for AQ production from glucose using a engineered E.coli strain co-expressing L-amino acid α-ligase (Lal) and L-alanine dehydrogenase (Ald) in the strain background of JKYPQ3 (pepA pepB pepD pepN dpp glnE glnB putA)[20]. The amino acids needed for AQ production were biosynthesized from glucose. However, it was challenging to balance the ratio of glutamine and alanine, which might affect AQ production. Moreover, the synthesis of amino acids was generally tightly regulated. Therefore, AQ accumulation was slow, and the productivity of AQ was low in the fermentation process. In this study, AQ was synthesized from glutamic acid and alanine using whole-cell biocatalytic process. Alanine was added to the reaction mixture as substrate, and glutamine was synthesized from externally added glutamic acid. A very small amount of glucose was used to supply ATP. The concentrations of the substrates (glutamate and alanine) can be easily controlled. The productivity of AQ in this study was 3.98 mM/h which was much higher than previously reported [20].

Table. 1 Production of AQ using engineered E.coli

Strain	Deletion of gene	Overexpression of genes	Process	AQ	References
E.coli JKYPQ3/pPE167	ΔpepAΔpepBΔpepDΔpepNΔdppΔproΔglnBΔglnEΔputA	L-amino acid α-ligase (Lal/BacD) and L-alanine dehydrogenase (Ald)	Fermentation from glucose	7.4 mM in test tube in 47h 100 mM (24.7g/L) in fermenter in 47h	[20]
E. brevis ATCC 14234	None	α-amino acid ester acyltransferase	Enzymatic production by purified enzyme from AlaOMe and Gln	83 mM (18.0g/L) in 1h	[32]
E.coli SP1 /pSaet	ΔpepD	α-amino acid ester acyltransferase	Enzymatic production from AlaOMe and Gln	320 mM (69.7g/L) in 40min	[33]
E.coli OPA	None	α-amino acid ester acyltransferase	Enzymatic production from AlaOMe and Gln	367.9 mM (79.8g/L) in 20min	[18]
E.coli p15/AQ10	ΔglsAΔglsBΔlpxMΔglnBΔglnEΔpepAΔpepBΔpepDΔpepNΔdpp	L-amino acid α-ligase (Lal/BacD) and glutamine synthetase (GlnA)	whole-cell biocatalytic conversion of glutamic acid and alanine	71.7 mM (14.2g/L) in test tube in 18h	This study

It was reported that expression of L-amino acid α-ligase exerted a negative effect on cell growth in the fermentation[20]. In the whole-cell bioconversion, cell growth (the enzyme manufacturing phase) and the AQ production phase were separated. Substrates were converted to AQ by resting cells in the production phase. Therefore, the growth inhibitory effect of L-amino acid α-ligase was reduced.

BacD enzymes have been reported to have insufficient substrate specificity and form by-products, such as different dipeptides or longer oligopeptides[30], which undoubtedly increases the cost of downstream separation and purification of target products. In this study, the extracellular concentrations of Ala-Ala reached 12.4 mM after 18 h of reaction, and no other dipeptides or longer oligopeptides were detected. The concentration of alanine decreased faster than that of glutamic acid, which suggested that the alanine catabolism should be reduced. Further studies are underway to improve the system including screening of BacD homologs with higher enzymatic activity and substrate specificity, enhancing AQ efflux using dipeptide efflux pump, reducing the degradation of alanine by blocking its catabolism, and scale-up of the bioconversion in fermenters.

In this study, we conducted systematic metabolic engineering of E.coli to develop a whole-cell biocatalysis for the synthesis of AQ from glutamic acid and alanine. Inactivation of peptidases and the dipeptide transport system, combined with screening of BacD homologs improved the yield of AQ. The supply of glutamine from glutamic acid was improved by overexpression of glutamine synthetase (GlnA), reduction of glutamine degradation by inactivating of glutaminases (ΔglsAΔglsB), and deregulation of glutamine biosynthesis (ΔglnEΔglnB). The final engineered E.coli strain p15/AQ10 produced 71.7mM AQ with a conversion rate of 71.7% for glutamic acid. This study offers new opportunities for the bio-industrial production of AQ. The metabolic engineering strategies developed in this study can be applied in the synthesis of other high-value-added dipeptides and oligopeptides.

Construction of plasmids and strains

Escherichia coli K12 (BW25113) was used for protein expression. All bacteria strains and plasmids used in this study are listed in Table. 2. Target genes (CgglnA, BsbacD, BabacD, BlabacD, BvbacD, VcbacD, BlabacD, PfbacD, BlobacD, PmbacD, BsabacD, and SrbacD ) were codon-optimized and synthesized by Generay (Shanghai, China), and then ligated into pYB1a between the Xho I and EcoR I sites via Gibson assembly[34]. Inactivation of genes was conducted using the CRISPR–Cas9 system[35].

Table. 2 Strains and plasmids used in this study

Strains/plasmids	Characteristics	Source
Strains
E.coli BW25113	IacI^qrrnB_T14∆lacZ_WJ16hsdR514∆araBAD_AH33∆rhaBAD_LD78	Invitrogen
AQ02	E. coli BW25113, ∆glnE, ∆glnB	This study
AQ04	E. coli BW25113, ∆glsA, ∆glsB	This study
AQ06	E. coli BW25113, ∆glnE, ∆glnB, ∆glsA, ∆glsB, ∆lpxM	This study
AQ09	E. coli BW25113, ∆pepA, ∆ pepB, ∆ pepD, ∆ pepN, ∆dpp	This study
AQ10	E. coli BW25113, ∆glnE, ∆glnB, ∆glsA, ∆glsB, ∆lpxM, ∆pepA, ∆ pepB, ∆ pepD, ∆ pepN, ∆dpp	This study
p11/AQ10	AQ10 expressing p11	This study
p12/AQ10	AQ10 expressing p12	This study
p13/AQ10	AQ10 expressing p13	This study
p14/AQ10	AQ10 expressing p14	This study
p15/AQ10	AQ10 expressing p15	This study
p16/AQ10	AQ10 expressing p16	This study
Plasmids
pYB1a	P15A origin, pBAD promoter, Amp^R	Our lab
pYB1s	P15A origin, pBAD promoter, Str^R	Our lab
p00	glnA from Corynebacterium glutamicum cloned into pYB1a	This study
p01	bacD from Bacillus subtilis cloned into pYB1a	This study
p02	bacD from Bacillus altitudinis cloned into pYB1a	This study
p03	bacD from Beta vulgaris cloned into pYB1a	This study
p04	bacD from Vibrio campbellii cloned into pYB1a	This study
p05	bacD from Streptomyces rubrolavendulae cloned into pYB1a	This study
p06	bacD from Bacillus safensis cloned into pYB1a	This study
p07	bacD from Bifidobacterium longum subsp. Infantis cloned into pYB1a	This study
p08	bacD from Brevibacillus laterosporus cloned into pYB1a	This study
p09	bacD from Perkinsus marinus cloned into pYB1a	This study
p10	bacD from Pseudomonas fluorescens cloned into pYB1a	This study
p11	CgglnA-BsbacD cloned into pYB1s	This study
p12	BsbacD-CgglnA cloned into pYB1s	This study
p13	CgglnA-BabacD cloned into pYB1s	This study
p14	BabacD-CgglnA cloned into pYB1s	This study
p15	BsbacD mRNA corresponding translation initiation rate was predicted to be 176300	This study
p16	BsbacD mRNA corresponding translation initiation rate was predicted to be 295800	This study

Culture condition

Strains were grown in LB medium (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl) at 37 °C and 220 rpm. Antibiotics (ampicillin 100 µg/mL, or streptomycin 40 µg/mL) were added as required. For protein expression, auto-inducing ZYM medium (per liter: tryptone 10 g, yeast extract 5 g, glycerol 5 g, glucose 0.5 g, L-arabinose 2 g, Na₂HPO₄ 25 mM, KH₂PO₄ 25 mM, NH₄Cl 50 mM, Na₂SO₄ 5 mM, MgSO₄ 2 mM, and trace elements including 0.05 mM FeCl₃, 0.02 mM CaCl₂, 0.01 mM MnCl₂, 0.01 mM ZnSO₄, and 0.002 mM each of CoCl₂, NiCl₂, Na₂Mo₄, Na₂SeO₃, and H₃BO₃) was used[36], and the strains were allowed to auto-induced at 30 °C for 12–16 h.

Whole‑cell biocatalysis conditions

Cells were harvested after induction by centrifugation at 5000×g for 10 min, washed once with 0.85% NaCl solution, and then used for the production of AQ via whole-cell biocatalytic conversion[37]. For AQ synthesis from glutamine and alanine, the conversion system contained 50 mM MOPS (morpholine propane sulfonic acid) buffer pH7.0, 50 mM glutamine, 50 mM alanine, 10 mM magnesium chloride, and 50 mM glucose with a starting OD_600nm= 30. The bioconversion reaction was performed at 30°C and 220 rpm in a test tube. Glucose was supplemented at a concentration of 10 mM every three hours. For glutamine synthesis, the cells were suspended in 1 mL bioconversion medium containing 50 mM MOPS buffer pH7.0, 50 mM sodium glutamate, 100 mM ammonium chloride, 10 mM magnesium chloride, 50 mM glucose to form a cell suspension with a starting OD_600nm= 30. For AQ production from glutamic acid and alanine, the conversion system contained 50 mM MOPS buffer pH9.0, 100 mM sodium glutamate, 100 mM alanine, 100 mM ammonium chloride, 10 mM magnesium chloride, and 50 mM glucose.

In the process of optimizing the whole-cell catalytic conditions, the bioconversion reaction was performed at different temperatures (20-45°C) and pH values (6.0-11.0). When optimizing the strategy of glucose feeding, three different strategies were investigated: 1) 50 mM glucose at one time; 2) 10mM glucose was added every 3 hours; and 3) 20 mM glucose was added every 3 hours. When the concentration of substrate was studied, 100 to 200 mM alanine was added at once, together with 100 mM sodium glutamate.

Analytical methods

Biomass was estimated by measuring the optical density at 600 nm. Proteins expression was analyzed by SDS-PAGE. The concentrations of glucose and acetate in the supernatant were determined by HPLC on a Bio-Rad Aminex HPX-87H Ion Exclusion column (7.8×300 mm; Hercules, CA, USA), with a refractive index detector. Analysis was performed at 55 °C with a mobile phase of 5 mM H₂SO₄ at a flow rate of 0.5 mL/min.

The AQ and amino acids including glutamine, glutamic acid, and alanine, were derivatized using 9-fluorenylmethoxy carbonyl chloroformate and measured by HPLC as described by Kazuhiko Tabata [38] , with minor modifications as follows. The mobile phase components A and B were acetonitrile and 50 mM sodium acetate, and the gradient program was slightly modified as follows: 0 min, solvent A-solvent B at 10: 90; 0 to 20 min, a linear increase in solvent A to A-B at 60: 40; 20 to 24 min, a linear increase to A-B at 100: 0; 24 to 27 min, held at A-B at 100:0; 27 to 28 min, a linear decrease in solvent B to A-B at 10: 90. The column temperature was set at 30°C, the injection volume was 5 μL, and the flow rate was 0.6 mL/min.

AQ, L-alanyl-L-glutamine; GlnA, glutamine synthetase; BacD, L-Amino Acid α-Ligase; SDS-PAGE, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis; HPLC, high-performance liquid chromatography.

Acknowledgements

This work was supported by the National Natural Science Foundation of China Grant (31670051) and the National Key Research and Development Program of China (2018YFA0901400).

Additional file

Additional file : Fig. S1. Phylogenetic tree of BacD homologs. Fig. S2. SDS-PAGE analysis of different BacD proteins in E.coli. Fig. S3. SDS-PAGE analysis of strains which co-expressing CgGlnA and BacD. Fig. S4. SDS-PAGE analysis of strains by RBS optimization. Fig. S5 Concentration of glucose and acetic acid in the conversion.

Authors’ contributions

J-M Z carried out the main work, collected and analyzed the data, and drafted the manuscript. WY, B-H W, QL, X-T Z, Q-X G, J-Z L participated in the research. B-XL supervised the work, design of the study, participated in data analysis, and revised the manuscript. J-Z H and Y T participated in the conception and finalized the manuscript. All authors read and approved the final manuscript.

Author details

Chinese Academy of Sciences Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its additional file.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

National Natural Science Foundation of China Grant (31670051) and the National Key Research and Development Program of China (2018YFA0901400).

Stehle P, Kuhn KS: Glutamine: an obligatory parenteral nutrition substrate in critical care therapy. Biomed Res Int 2015, 2015:545467.
Labow BI, Souba WW: Glutamine. World Journal of Surgery 2014, 24:1503-1513.
Fuentes-Orozco C, Anaya-Prado R, González-Ojeda A, Arenas-Márquez H, Cabrera-Pivaral C, Cervantes-Guevara G, Barrera-Zepeda LM: l-Alanyl-l-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. Clinical Nutrition 2004, 23:13-21.
Lasierra JLF, Carmona TG: l-Alanyl-l-glutamine dipeptide-supplemented total parenteral nutrition. In Diet and Nutrition in Critical Care 2014 2014: 1-11.
Moore SR, Guedes MM, Costa TB, Vallance J, Maier EA, Betz KJ, Aihara E, Mahe MM, Lima AA, Oria RB, Shroyer NF: Glutamine and alanyl-glutamine promote crypt expansion and mTOR signaling in murine enteroids. Am J Physiol Gastrointest Liver Physiol 2015, 308:G831-839.
Mundi MS, Shah M, Hurt RT: When is it appropriate to use glutamine in critical illness? Nutr Clin Pract 2016, 31:445-450.
R R W J van der Hulst, Meyenfeldt M F V, Soeters P B: Glutamine: a gut essential amino acid.
Zhou Y, Zhang P, Deng G, Liu X, Lu D: Improvements of immune status, intestinal integrity and gain performance in the early-weaned calves parenterally supplemented with L-alanyl-L-glutamine dipeptide. Vet Immunol Immunopathol 2012, 145:134-142.
Furst P, Pogan K, Stehle P: Glutamine dipeptides in clinical nutrition. Nutrition 1997, 13(7–8): 731-737.
Li S L, Li C, Liu Y S, Wang X L, Cao Z A: Separation of (l)-glutamine from fermentation broth by nanofiltration. Journal of Membrane Science 2003, 222(1-2): 191-201.
Tan B, Liu H, He G, Xiao H, Xiao D, Liu Y, Wu J, Fang J, Yin Y: Alanyl-glutamine but not glycyl-glutamine improved the proliferation of enterocytes as glutamine substitution in vitro. Amino Acids 2017, 49:2023-2031.
Sano T, Sugaya T, Inoue K, Mizutaki S I , Kasai M: Cheminform abstract: process research and development of l-alanyl-l-glutamine, a component of parenteral nutrition. ChemInform 2000, 31(39).
Neuh User-Berthold M, Eufinger H: Utilization of alanyl-L-glutamine and glycyl-L-glutamine during long-term parenteral nutrition in the growing rat. Amino Acids (Vienna) 1992, 3(3):293-302.
Yokozeki K, Hara S: A novel and efficient enzymatic method for the production of peptides from unprotected starting materials. J Biotechnol 2005, 115:211-220.
Fields G B, Noble R L: Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research 1990, 35(3): 161-214.
Wang M, Qi W, Yu Q, Su R, He Z: Kinetically controlled enzymatic synthesis of dipeptide precursor of L-alanyl-L-glutamine. Biotechnol Appl Biochem 2011, 58:449-455.
Akabori S, S Sakakibara, Y Shimonishi: Protection of amidenitrogen for peptide synthesis. A novel synthesis of peptide containing Cterminal glutamine. Bull. Chem. Soc. Jpn 1961. 34:739.
Li Y, Yuan W, Gao J, Fan C, Wu W, Bai F: Production of l-alanyl-l-glutamine by recycling E. coli expressing alpha-amino acid ester acyltransferase. Bioresour Technol 2017, 245:1603-1609.
Tanaka T, Takagi K, Saddam HM, Takeda Y, Wakayama M: Purification and characterization of Elizabethkingia L-amino acid esterase: an enzyme useful for enzymatic synthesis of the dipeptide, Valyl-Glycine. Appl Biochem Biotechnol 2017, 183:362-373.
Tabata K, Hashimoto S: Fermentative production of L-alanyl-L-glutamine by a metabolically engineered Escherichia coli strain expressing L-amino acid alpha-ligase. Appl Environ Microbiol 2007, 73:6378-6385.
Lutz W, Jazdzewski B: Degradation of intracellular proteins. Pol Tyg Lek 1980, 35(33): 1275-1278.
Smith M W, Tyreman D R, Payne G M, Marshall N J, Payne J W: Substrate specificity of the periplasmic dipeptide-binding protein from Escherichia coli: experimental basis for the design of peptide prodrugs. Microbiology 1999, 145 ( Pt 10)(10): 2891.
Jiang P, Ninfa A J: Escherichia coli PII signal transduction protein controlling nitrogen assimilation acts as a sensor of adenylate energy charge in vitro. Biochemistry 2007, 46(45):12979-96.
Jaggi, R: The two opposing activities of adenylyl transferase reside in distinct homologous domains, with intramolecular signal transduction. EMBO (European Molecular Biology Organization) Journal 1997, 16(18):5562-5571.
Pahel G, Tyler B: A new glnA-linked regulatory gene for glutamine synthetase in Escherichia coli. Proc Natl Acad Sci U S A 1979, 76:4544-4548.
Brown G, Singer A, Proudfoot M, Skarina T, Kim Y, Chang C: Functional and structural characterization of four glutaminases from Escherichia coli and bacillus subtilis. Biochemistry 2008, 47(21): 5724-35.
Espah Borujeni A, Channarasappa AS, Salis HM: Translation rate is controlled by coupled trade-offs between site accessibility, selective RNA unfolding and sliding at upstream standby sites. Nucleic Acids Res 2014, 42:2646-2659.
Espah Borujeni A, Salis HM: Translation initiation is controlled by RNA folding kinetics via a ribosome drafting mechanism. J Am Chem Soc 2016, 138:7016-7023.
Espah Borujeni A, Cetnar D, Farasat I, Smith A, Lundgren N, Salis HM: Precise quantification of translation inhibition by mRNA structures that overlap with the ribosomal footprint in N-terminal coding sequences. Nucleic Acids Res 2017, 45:5437-5448.
Yokozeki K, & Hara S: A novel and efficient enzymatic method for the production of peptides from unprotected starting materials. Journal of Biotechnology 2005, 115(2): 211-220.
Hayashi M, Tabata K, Yagasaki M, Yonetani Y: Effect of multidrug-efflux transporter genes on dipeptide resistance and overproduction in Escherichia coli. FEMS Microbiol Lett 2010, 304:12-19.
Yokozeki K, Hara S: A novel and efficient enzymatic method for the production of peptides from unprotected starting materials. Journal of Biotechnology 2005, 115(2):211-220.
Hirao Y, Mihara Y, Kira I, Abe I, Yokozeki, K: Enzymatic production of L-Alanyl-L-glutamine by recombinant E. coli expressing α-amino acid ester acyltransferase from Sphingobacterium siyangensis. Journal of the Agricultural Chemical Society of Japan 2013, 77(3):618-623.
Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, Smith HO: Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 2009, 6:343-345.
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F: Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013, 8:2281-2308.
Studier F W: Protein production by auto-induction in high-density shaking cultures. Protein Expr Purif 2005, 41(1): 207-234.
Lin B, Tao Y: Whole-cell biocatalysts by design. Microb Cell Fact.2017, 16:106.
Tabata K, Ikeda H, Hashimoto S: ywfE in Bacillus subtilis codes for a novel enzyme, L-amino acid α-ligase. J Bacteriol 2005, 187:5195-5202.
Abouhamad W N, Manson M D: The dipeptide permease of Escherichia coli ciosely resembies other bacterial transport systems and shows growth-phase-dependent expression. Molecular Microbiology 1994, 14.

Supplementalmaterial.pdf

Download PDF

Journal Publication

published 11 Jun, 2020

Read the published version in Microbial Cell Factories →

Editorial decision: Accept
14 May, 2020
Editor assigned by journal
04 May, 2020
Submission checks completed at journal
03 May, 2020
Editor invited by journal
03 May, 2020

You are reading this latest preprint version

Metabolic engineering of Escherichia coli for efficient production of L-alanyl-L-glutamine

Status:

Journal Publication

Version 3

Abstract

Figures

Background

Results

Discussion

Conclusions

Materials And Methods

Abbreviations

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 3